Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda for Type 2 Diabetes in India
21 hours agoBusiness
30LENS
5 SourcesIndia
TBNthebalanced.news

Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda for Type 2 Diabetes in India

Dr Reddy's Laboratories has launched Obeda, an oral semaglutide biosimilar for type 2 diabetes in India, available in 3 mg, 7 mg, and 14 mg doses priced between Rs 99 and Rs 225 per tablet. Approved by CDSCO after a Phase III trial demonstrating comparable efficacy and safety to the innovator drug, Obeda is indicated as an adjunct to diet and exercise to improve glycaemic control. This launch expands Dr Reddy's GLP-1 receptor agonist portfolio, aiming to offer affordable, high-quality treatment options for metabolic diseases in India.

Political Bias
0%100%0%
Sentiment
75%
AI analysis of 5 sources · Published under editorial oversight by The Balanced News
Analysed 20 May 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 5 sources
● Left 0%● Center 100%● Right 0%

The articles primarily present a corporate and healthcare perspective, focusing on Dr Reddy's product launch without political framing. They include statements from company executives and regulatory approval details, reflecting industry and regulatory viewpoints. There is no evident political bias, as coverage centers on medical innovation and market expansion rather than political implications.

Sentiment — Positive (75/100)

The overall tone across the articles is positive and informative, highlighting the drug's approval, clinical trial success, and potential benefits for diabetes patients. The coverage emphasizes innovation, affordability, and expanded treatment options, with no critical or negative sentiment observed.

How 5 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
thehinduDr. Reddy's launches Semaglutide tablets in IndiaCenterPositive
economictimesDr Reddy's launches oral semaglutide in IndiaCenterPositive
economictimesDr Reddy's launches oral semaglutide biosimilar Obeda in IndiaCenterPositive
businessstandardDr Reddy's unveils oral diabetes drug Obeda for type 2 patients in IndiaCenterPositive
news18Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaCenterPositive

Coverage timeline

news18 broke this story on 20 May, 12:34 pm. Other outlets followed.

  1. 1
    news1820 May, 12:34 pm
    Dr Reddy's launches oral semaglutide biosimilar Obeda in India
  2. 2
    businessstandard20 May, 01:26 pm
    Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India
  3. 3
    economictimes20 May, 01:32 pm
    Dr Reddy's launches oral semaglutide biosimilar Obeda in India
  4. 4
    economictimes20 May, 02:48 pm
    Dr Reddy's launches oral semaglutide in India
  5. 5
    thehindu20 May, 04:46 pm
    Dr. Reddy's launches Semaglutide tablets in India

Lens Score breakdown

30/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Dr Reddy's Laboratories Ltd

Story context

Category
Business
Location
India
Sources analysed
5
Last analysed
20 May 2026
Key entities
SemaglutideDr. Reddy's LaboratoriesType 2 diabetesTablet (pharmacy)IndiaDiabetesCanadaGlucagon-like peptide-1Metabolic disorderIndian rupeePhases of clinical researchBiosimilar